The pathway to secondary prevention of Alzheimer's disease
Abstract Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficaci...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12069 |
| _version_ | 1819290559780487168 |
|---|---|
| author | Eric McDade Martin M. Bednar H. Robert Brashear David S. Miller Paul Maruff Christopher Randolph Zahinoor Ismail Maria C. Carrillo Christopher J. Weber Lisa J. Bain Ann Marie Hake |
| author_facet | Eric McDade Martin M. Bednar H. Robert Brashear David S. Miller Paul Maruff Christopher Randolph Zahinoor Ismail Maria C. Carrillo Christopher J. Weber Lisa J. Bain Ann Marie Hake |
| author_sort | Eric McDade |
| collection | DOAJ |
| description | Abstract Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre‐clinical AD. This review will address the biological approach to defining pre‐clinical AD, detection, identification of at‐risk individuals, and lessons learned from trials such as A4 and TOMMORROW. |
| first_indexed | 2024-12-24T03:24:40Z |
| format | Article |
| id | doaj.art-a1ef83d3bba8417fb95f0903fde9ba8b |
| institution | Directory Open Access Journal |
| issn | 2352-8737 |
| language | English |
| last_indexed | 2024-12-24T03:24:40Z |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj.art-a1ef83d3bba8417fb95f0903fde9ba8b2022-12-21T17:17:22ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372020-01-0161n/an/a10.1002/trc2.12069The pathway to secondary prevention of Alzheimer's diseaseEric McDade0Martin M. Bednar1H. Robert Brashear2David S. Miller3Paul Maruff4Christopher Randolph5Zahinoor Ismail6Maria C. Carrillo7Christopher J. Weber8Lisa J. Bain9Ann Marie Hake10Department of Neurology Washington University School of Medicine Saint Louis Missouri USATakeda Pharmaceuticals International Co. Americas, Inc. Cambridge Massachusetts USAJanssen Research and Development South San Francisco California USASignant Health Blue Bell Pennsylvania USACogstate Ltd Melbourne Victoria AustraliaMedAvante‐ProPhase Hamilton New Jersey USACumming School of Medicine The University of Calgary Calgary CanadaAlzheimer's Association Chicago Illinois USAAlzheimer's Association Chicago Illinois USAIndependent Science Writer Elverson Pennsylvania USAEli Lilly and Company Indianapolis Indiana USAAbstract Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre‐clinical AD. This review will address the biological approach to defining pre‐clinical AD, detection, identification of at‐risk individuals, and lessons learned from trials such as A4 and TOMMORROW.https://doi.org/10.1002/trc2.12069clinical trialsAlzheimer's diseasebiomarkersresearch roundtable |
| spellingShingle | Eric McDade Martin M. Bednar H. Robert Brashear David S. Miller Paul Maruff Christopher Randolph Zahinoor Ismail Maria C. Carrillo Christopher J. Weber Lisa J. Bain Ann Marie Hake The pathway to secondary prevention of Alzheimer's disease Alzheimer’s & Dementia: Translational Research & Clinical Interventions clinical trials Alzheimer's disease biomarkers research roundtable |
| title | The pathway to secondary prevention of Alzheimer's disease |
| title_full | The pathway to secondary prevention of Alzheimer's disease |
| title_fullStr | The pathway to secondary prevention of Alzheimer's disease |
| title_full_unstemmed | The pathway to secondary prevention of Alzheimer's disease |
| title_short | The pathway to secondary prevention of Alzheimer's disease |
| title_sort | pathway to secondary prevention of alzheimer s disease |
| topic | clinical trials Alzheimer's disease biomarkers research roundtable |
| url | https://doi.org/10.1002/trc2.12069 |
| work_keys_str_mv | AT ericmcdade thepathwaytosecondarypreventionofalzheimersdisease AT martinmbednar thepathwaytosecondarypreventionofalzheimersdisease AT hrobertbrashear thepathwaytosecondarypreventionofalzheimersdisease AT davidsmiller thepathwaytosecondarypreventionofalzheimersdisease AT paulmaruff thepathwaytosecondarypreventionofalzheimersdisease AT christopherrandolph thepathwaytosecondarypreventionofalzheimersdisease AT zahinoorismail thepathwaytosecondarypreventionofalzheimersdisease AT mariaccarrillo thepathwaytosecondarypreventionofalzheimersdisease AT christopherjweber thepathwaytosecondarypreventionofalzheimersdisease AT lisajbain thepathwaytosecondarypreventionofalzheimersdisease AT annmariehake thepathwaytosecondarypreventionofalzheimersdisease AT ericmcdade pathwaytosecondarypreventionofalzheimersdisease AT martinmbednar pathwaytosecondarypreventionofalzheimersdisease AT hrobertbrashear pathwaytosecondarypreventionofalzheimersdisease AT davidsmiller pathwaytosecondarypreventionofalzheimersdisease AT paulmaruff pathwaytosecondarypreventionofalzheimersdisease AT christopherrandolph pathwaytosecondarypreventionofalzheimersdisease AT zahinoorismail pathwaytosecondarypreventionofalzheimersdisease AT mariaccarrillo pathwaytosecondarypreventionofalzheimersdisease AT christopherjweber pathwaytosecondarypreventionofalzheimersdisease AT lisajbain pathwaytosecondarypreventionofalzheimersdisease AT annmariehake pathwaytosecondarypreventionofalzheimersdisease |